// App-Quantinova.ai

2570 : Safety of Clofarabine with Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (Vandevol study of the French SFCE Acute Leukemia Committee).

Researchers

Presenter

  • Guy Leverger

Principal Investigators

  • Claire Galambrun

  • Pierre Rohrlich

  • Genevieve Plat

  • Claudine Schmitt

  • Caroline Thomas

  • Cecile Verite

  • Benoit Brethon

  • Virginie Gandemer

  • Yves Bertrand

  • Andre Baruchel

Medical Centers

  • Pediatric Hematology,, Hopital Robert Debre, paris,

  • Pediatric Hematology Unit, CHU Jean Minjoz Hospital, Besancon, France

  • Hematology Clinic, CHU Nantes, Nantes, France

  • Pediatric Hematology and Oncology Department, Trousseau Hospital - APHP and UPMC Univ Paris 06, Paris, France

  • Medical Oncology, Bordeaux University Hospital, Bordeaux, France

  • Department of Pediatric Hematology-Immunology, Robert Debre Hospital, Paris, France

  • Pediatric Hematology Oncology, CHU de Nancy, Vandoeuvre, France,

  • CHU-Hopital Sud, Department of Pediatric Hematology/Oncology, Rennes, France

  • Pediatric Hematology Department, Hopital de La Timone, Marseille, France

  • Department of Pediatric Onco-Hematology, CHU-Hopital Purpan, Toulouse, France

  • Institute of Pediatric Hematology and Oncology, Lyon Hospital, Lyon, France

  • Pediatrics Hematology, CHU Lille, Lille, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Acute Leukemia

  • Hyperglycemia

  • Neutropenia

  • Post-transplant lymphoproliferative disorder

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Mitoxantrone

  • Asparaginase

  • Clofarabine

  • Cytarabine liposomal

  • Hydroxyzine

  • Etoposide

  • Etoposide phosphate

  • Roxithromycin

  • Allopurinol

Outcome

  • N/A

Study Design

  • fixed dose

Phase

  • NA

Study Id's

  • NCT01279096

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved